DE602005019582D1 - Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell - Google Patents

Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell

Info

Publication number
DE602005019582D1
DE602005019582D1 DE602005019582T DE602005019582T DE602005019582D1 DE 602005019582 D1 DE602005019582 D1 DE 602005019582D1 DE 602005019582 T DE602005019582 T DE 602005019582T DE 602005019582 T DE602005019582 T DE 602005019582T DE 602005019582 D1 DE602005019582 D1 DE 602005019582D1
Authority
DE
Germany
Prior art keywords
fokal
udca
unlocked
ischemic model
nerve protection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005019582T
Other languages
English (en)
Inventor
Seo Hong Yoo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE602005019582D1 publication Critical patent/DE602005019582D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/723—Xanthans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/413—Gall bladder; Bile
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602005019582T 2004-08-30 2005-08-30 Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell Active DE602005019582D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60556604P 2004-08-30 2004-08-30
US62999804P 2004-11-22 2004-11-22
PCT/US2005/030679 WO2006026555A2 (en) 2004-08-30 2005-08-30 Neuroprotective effect of solubilized udca in focal ischemic model

Publications (1)

Publication Number Publication Date
DE602005019582D1 true DE602005019582D1 (de) 2010-04-08

Family

ID=35702324

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005019582T Active DE602005019582D1 (de) 2004-08-30 2005-08-30 Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell

Country Status (14)

Country Link
US (1) US8173627B2 (de)
EP (1) EP1789057B1 (de)
JP (1) JP2008511651A (de)
KR (1) KR101414810B1 (de)
CN (1) CN101035541B (de)
AT (1) ATE458489T1 (de)
AU (1) AU2005279961B2 (de)
BR (1) BRPI0514725A (de)
CA (1) CA2577268A1 (de)
DE (1) DE602005019582D1 (de)
ES (1) ES2339790T3 (de)
IL (1) IL181434A (de)
RU (1) RU2428987C2 (de)
WO (1) WO2006026555A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20070072828A1 (en) * 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7145125B2 (en) * 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
AU2005279961B2 (en) 2004-08-30 2010-05-13 Seo Hong Yoo Neuroprotective effect of solubilized UDCA in focal ischemic model
US9629838B2 (en) 2004-09-16 2017-04-25 Morehouse School Of Medicine Composition for reducing nervous system injury and method of making and use thereof
ATE506955T1 (de) * 2004-10-15 2011-05-15 Seo Hong Yoo Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin
AU2005302452B2 (en) * 2004-11-01 2010-12-09 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in Amyotrophic Lateral Sclerosis
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
BR112013025368A8 (pt) * 2011-04-01 2018-06-12 The Medicines Co Medicamento, método para preparar um medicamento útil para reduzir danos por derrame em um sujeito com derrame, método para preparar um medicamento útil para reduzir a pressão sanguínea e reduzir danos por derrame em um sujeito com derrame
PT2770988T (pt) 2011-10-24 2016-09-05 Som Innovation Biotech S L Nova terapêutica para a amiloidose associada à transtirretina
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CN110742891B (zh) 2013-08-21 2024-04-05 莫尔豪斯医学院 用于减轻神经系统损伤的组合物及该组合物的制造方法和用途
US10603316B2 (en) 2013-08-21 2020-03-31 Morehouse School Of Medicine Composition and methods for preventing or reducing the incidence of transient ischemic attacks
US10188757B2 (en) 2013-10-22 2019-01-29 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
KR101555945B1 (ko) 2014-11-27 2015-09-25 부산대학교 산학협력단 Ｔｕｄｃａ를 이용한 줄기세포 생물작용 활성 증가, 및 이를 포함하는 줄기세포 치료 보조제
WO2017091644A1 (en) * 2015-11-23 2017-06-01 Aztherapies, Inc. Compositions and methods for treating ischemic stroke
CN105853473B (zh) * 2016-03-31 2019-12-13 海南合瑞制药股份有限公司 一种奥拉西坦的药物组合物及其制备方法
EP3506894B1 (de) 2016-08-31 2023-08-23 The General Hospital Corporation Macrophagen/mikroglia bei nervenentzündungen im zusammenhang mit neurodegenerativen erkrankungen
KR20180036580A (ko) * 2016-09-30 2018-04-09 주식회사 유스바이오팜 수가용화(水加溶化)된 우르소데옥시콜산을 함유하는 염증성 피부질환 또는 중증 소양증 예방 또는 치료용 조성물
US11185553B2 (en) 2016-10-31 2021-11-30 Samsung Life Public Welfare Foundation Pharmaceutical composition for preventing or treating ischemic-reperfusion injury comprising bile acids
WO2018147685A1 (ko) * 2017-02-09 2018-08-16 주식회사 유스바이오팜 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
KR102252450B1 (ko) * 2017-02-09 2021-05-14 주식회사 아미코젠파마 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
WO2019017995A1 (en) 2017-07-20 2019-01-24 Aztherapies, Inc. FORMULATIONS OF CROMOLYNE SODIUM POWDER AND IBUPROFEN
JP2018138592A (ja) * 2018-05-08 2018-09-06 モアハウス スクール オブ メディスンＭｏｒｅｈｏｕｓｅ Ｓｃｈｏｏｌ Ｏｆ Ｍｅｄｉｃｉｎｅ 神経系損傷を減少させるための組成物及びその製造方法及び使用
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
US10980757B2 (en) 2018-09-06 2021-04-20 RTU Pharma SA Ready-to-use tranexamic acid intravenous solution
CN109288850B (zh) * 2018-11-21 2019-10-29 浙江大学 熊脱氧胆酸或其药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物
JP2020079289A (ja) * 2020-02-07 2020-05-28 モアハウス スクール オブ メディスンＭｏｒｅｈｏｕｓｅ Ｓｃｈｏｏｌ Ｏｆ Ｍｅｄｉｃｉｎｅ 神経系損傷を減少させるための組成物及びその製造方法及び使用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4092428A (en) 1973-11-02 1978-05-30 Yamanouchi Pharmaceutical Co., Ltd. Process of preparing stable prostaglandin E group-containing formulation
US4036954A (en) 1973-11-02 1977-07-19 Yamanouchi Pharmaceutical Co., Ltd. Stable prostaglandin E group-containing formulation
US4113882A (en) 1974-10-21 1978-09-12 Yamanouchi Pharmaceutical Co., Ltd. Stabilized oral prostaglandin formulation and the process for the preparation thereof
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
JPS5522616A (en) 1978-08-04 1980-02-18 Tokyo Tanabe Co Ltd Bile acid inclusion compound and injection containing the same
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
FR2521430A1 (fr) 1982-02-12 1983-08-19 Pan Medica Solution aqueuse d'acide ursodesoxycholique a usages therapeutiques, son procede de preparation et application au traitement des lithiases biliaires
GB8313217D0 (en) 1983-05-13 1983-06-22 Glaxo Group Ltd Pharmaceutical compositions
GB8417895D0 (en) 1984-07-13 1984-08-15 Marples B A Pharmaceutical anti-fungal composition
JPS61171421A (ja) 1985-08-23 1986-08-02 Yamanouchi Pharmaceut Co Ltd 安定なプロスタグランジンｅ類製剤の製造方法
JPS62153220A (ja) 1985-12-27 1987-07-08 Tokyo Tanabe Co Ltd 胆汁酸内用水剤
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
JPH0747539B2 (ja) 1986-10-22 1995-05-24 東京田辺製薬株式会社 胆汁酸固形製剤
JPS63243031A (ja) 1987-03-28 1988-10-07 Tokyo Tanabe Co Ltd 胆汁酸の固形製剤
HU203204B (en) 1987-09-15 1991-06-28 Sandoz Ag Process for producing suppository containing calcitonin and taurocholic acid
DE3886880T2 (de) 1987-10-15 1994-07-14 Syntex Inc Pulverförmige Zubereitungen zur intranasalen Verabreichung von Polypeptiden.
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US5446026A (en) 1989-08-09 1995-08-29 Advanced Peptides & Biotechnology Sciences Potent non-opiate analgesic
US5157022A (en) 1989-11-22 1992-10-20 Adrian Barbul Method for reducing blood cholesterol using arginine
EP0527153B1 (de) 1990-04-04 1996-07-24 Berwind Pharmaceutical Services, Inc. Wässrige filmbildende überzugszusammensetzungen aus maltodextrin und zellulosederivaten
US5057321A (en) 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
IT1245891B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali.
IT1245890B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
IT1245889B (it) 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti sali di acidi biliari.
CH680704A5 (de) 1991-05-15 1992-10-30 Medichemie Ag
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
HU209251B (en) 1992-03-13 1994-04-28 Synepos Ag Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
US5292534A (en) 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5342934A (en) 1992-06-19 1994-08-30 The Trustees Of Columbia University In The City Of New York Enantioselective receptor for amino acid derivatives, and other compounds
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5302400A (en) 1992-06-22 1994-04-12 Digestive Care Inc. Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids
US5578304A (en) 1992-06-22 1996-11-26 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
IT1255968B (it) 1992-11-27 1995-11-17 Composizioni farmaceutiche contenenti acido ursodesossicolico
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
AU683049B2 (en) 1993-03-31 1997-10-30 Mitsubishi-Tokyo Pharmaceuticals, Inc. Cholestasis ameliorant
LU88375A1 (fr) 1993-07-12 1994-04-01 Michel Urso Prof Medecin Et Ch Produit énergétique stimulant la puissance virile
US5846964A (en) 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
DK0640344T3 (da) 1993-08-30 1999-07-05 Medichemie Ag Ursodesoxycholsyreholdigt lægemiddel i flydende administreringsform
GB9405833D0 (en) 1994-03-24 1994-05-11 Pfizer Ltd Separation of the enantiomers of amlodipine
DE4432708A1 (de) 1994-09-14 1996-03-21 Hoechst Ag Modifizierte Gallensäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
US5965164A (en) 1994-10-28 1999-10-12 Fuisz Technologies Ltd. Recipient-dosage delivery system
US5653987A (en) 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5686588A (en) 1995-08-16 1997-11-11 Yoo; Seo Hong Amine acid salt compounds and process for the production thereof
JP2000507938A (ja) 1996-03-22 2000-06-27 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 結腸直腸の化学的保護のためのウルソデオキシコール酸化合物及びｎｓａｉｄの組合せ
US5843929A (en) 1996-03-22 1998-12-01 Mayo Foundation For Medical Education And Research Chemoprevention of metachronous adenomatous colorectal polyps
US6596712B2 (en) 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
US5750104A (en) 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US5898028A (en) 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US20010011146A1 (en) 1997-04-23 2001-08-02 Tong H. Joh Neuroprotective compounds and uses thereof
DE29717252U1 (de) 1997-09-26 1998-02-19 Falk Pharma Gmbh Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
KR100314496B1 (ko) 1998-05-28 2001-11-22 윤동진 항혈전성이 있는 헤파린 유도체, 그의 제조방법 및 용도
DE19981169B4 (de) 1998-05-28 2007-09-13 Mediplex Corporation, Korea Kovalent an Gallensäuren oder Sterine gebundenes Heparin, dessen Verwendung und diese enthaltende pharmazeutische Zusammensetzung
US6407117B1 (en) 1998-06-18 2002-06-18 The George Washington University Method of administering camptothecin compounds for the treatment of cancer with reduced side effects
AU4727799A (en) 1998-06-30 2000-01-17 Eli Lilly And Company Azepine derivatives having effects on serotonin related systems
US7772220B2 (en) 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US6251428B1 (en) * 1998-07-24 2001-06-26 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20070072828A1 (en) 1998-07-24 2007-03-29 Yoo Seo H Bile preparations for colorectal disorders
US7303768B2 (en) 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20050158408A1 (en) 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US6210699B1 (en) 1999-04-01 2001-04-03 Watson Pharmaceuticals, Inc. Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
WO2001000809A1 (en) 1999-06-30 2001-01-04 University Of Utah Research Foundation Self-induced deletion of dna
EP1471870B1 (de) * 2000-01-10 2014-08-20 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Verwendung von lipid-konjugaten in der behandlung von krankheiten
RU2277913C2 (ru) * 2000-02-04 2006-06-20 Сео Хонг Ю Получение водного прозрачного раствора лекарственных форм с желчными кислотами
WO2002005660A2 (en) 2000-07-18 2002-01-24 The Nutrasweet Company Drying of neotame with co-agents
US20030044413A1 (en) * 2000-08-15 2003-03-06 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
AU2002351986A1 (en) 2002-06-19 2004-01-06 Braun Gmbh Method and device for producing injection-molded parts during an injection molding method, particularly toothbrushes or toothbrush bodies
WO2004012686A2 (en) 2002-08-06 2004-02-12 Nitromed, Inc. Nitrosated and/or nitrosylated ursodeoxycholic acid compounds, compositions and methods of use
US20060135494A1 (en) * 2002-11-07 2006-06-22 Steer Clifford J Methods of treating injuries of the nervous system associated with hemorrhage
EP1615497A2 (de) 2003-04-02 2006-01-18 Regents Of The University Of Minnesota Verfahren zur förderung der lebensfähigkeit von zellen
AU2005279961B2 (en) 2004-08-30 2010-05-13 Seo Hong Yoo Neuroprotective effect of solubilized UDCA in focal ischemic model
ATE506955T1 (de) 2004-10-15 2011-05-15 Seo Hong Yoo Zusammensetzungen zur verringerung der toxizität von cisplatin, carboplatin und oxaliplatin
AU2005302452B2 (en) 2004-11-01 2010-12-09 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in Amyotrophic Lateral Sclerosis
CA2588168A1 (en) 2004-11-24 2006-06-01 Seo Hong Yoo Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US7308768B2 (en) * 2005-02-04 2007-12-18 Target Brands, Inc. Lenticular sign

Also Published As

Publication number Publication date
JP2008511651A (ja) 2008-04-17
KR101414810B1 (ko) 2014-07-18
WO2006026555A2 (en) 2006-03-09
AU2005279961A1 (en) 2006-03-09
AU2005279961B2 (en) 2010-05-13
CN101035541B (zh) 2012-05-30
RU2428987C2 (ru) 2011-09-20
BRPI0514725A (pt) 2008-06-24
IL181434A (en) 2012-05-31
CN101035541A (zh) 2007-09-12
ATE458489T1 (de) 2010-03-15
IL181434A0 (en) 2007-07-04
US8173627B2 (en) 2012-05-08
KR20070053238A (ko) 2007-05-23
WO2006026555A3 (en) 2006-07-13
EP1789057B1 (de) 2010-02-24
ES2339790T3 (es) 2010-05-25
CA2577268A1 (en) 2006-03-09
US20060051319A1 (en) 2006-03-09
EP1789057A2 (de) 2007-05-30
RU2007106563A (ru) 2008-10-10

Similar Documents

Publication Publication Date Title
DE602005019582D1 (de) Nervenschutzwirkung von aufgelöster udca bei einem fokalen ischämischen modell
WO2005055808A3 (en) Compositions and methods to diagnose and treat lung cancer
EA201000515A1 (ru) Активаторы глюкокиназы
WO2008018067A3 (en) Cerebral electrodes and methods of operating same
EA201101187A1 (ru) Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
ATE381935T1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
WO2006122046A3 (en) Vascular disease therapies
WO2009079452A3 (en) Treatment and prevention of hiv infection
ATE420101T1 (de) Isolierung von nervenstammzellen unter verwendung von gangliosiden und anderen oberflächenmarkern
MX2008015392A (es) Tratamiento de enfermedades isquemicas que usan eritropoyetina.
BR9906926A (pt) Composições e métodos para tratamento de células tendo dna de minuto duplo
BRPI0607648A2 (pt) composição dermatológica, sal, bem como o uso destas composições
WO2004094610A3 (en) Wnt as a factor for cardiac myogenesis
WO2007022204A3 (en) Computer-implemented model of the central nervous system
ATE487485T1 (de) Verwendung von d-ribose zur behandlung von vorhofflimmern
WO2008011134A3 (en) Use of late passage mesenchymal stem cells (mscs) for treatment of cardiac rhythm disorders
Spillius Comments on Owen Renik.
WO2002062205A3 (en) Methods for diagnosing and treating heart disease
DE502006008777D1 (de) Phenylen-bis-oxazolidin-derivate und ihre verwendung als antikoagulantien
CN203970747U (zh) 一种用于帮助患者起床的扶手装置
Rind et al. Comparative antihyperglycemic activity of aqueous extracts of garlic (Allium sativum) and ginger (Zingiber Officinale) in alloxan-induced male rabbits
RU2005107671A (ru) Способ лечения алкогольного делирия
WO2006096458A3 (en) Treatment of hyperproliferative diseases with anthraquinones
BRPI0407199A (pt) (benzoimidazol-2-il)-fenil-aminas n-substituìdas, processo para a sua preparação, sua aplicação como medicamento ou diagnóstico bem como o medicamento contendo as mesmas
CN203487902U (zh) 一种档位插销

Legal Events

Date Code Title Description
8364 No opposition during term of opposition